Abstract
Duchenne muscular dystrophy (DMD) is characterized by the loss of a functional dystrophin protein; the muscles of DMD patients progressively degenerate as a result of mechanical stress during contractions, and the condition eventually leads to premature death. By means antisense oligonucleotides (AONs), it is possible to modulate pre-mRNA splicing eliminating mutated exons and restoring dystrophin open reading frame. To overcome the hurdles in using AONs for therapeutic interventions, we exerted engineered human DMD stem cells with a lentivirus, which permanently and efficiently delivered the cloned AONs. Here we describe for the first time the exosome-mediated release of AONs from engineered human DMD CD133+ stem cells allowing the rescue of murine dystrophin expression. Finally, upon release, AONs could be internalized by host cells suggesting a potential role of exosomes acting as vesicular carriers for DMD gene therapy.
Keywords: Bystander effect, Myogenic stem cells, Delivery of exon skipping machinery.
Current Gene Therapy
Title:Stem Cell-Mediated Exon Skipping of the Dystrophin Gene by the Bystander Effect
Volume: 15 Issue: 6
Author(s): Mirella Meregalli, Andrea Farini, Clementina Sitzia, Cyriaque Beley, Paola Razini, Letizia Cassinelli, Federica Colleoni, Paola Frattini, Nadia Santo, Elisabetta Galbiati, Davide Prosperi, Alessandro Tavelli, Marzia Belicchi, Luis Garcia and Yvan Torrente
Affiliation:
Keywords: Bystander effect, Myogenic stem cells, Delivery of exon skipping machinery.
Abstract: Duchenne muscular dystrophy (DMD) is characterized by the loss of a functional dystrophin protein; the muscles of DMD patients progressively degenerate as a result of mechanical stress during contractions, and the condition eventually leads to premature death. By means antisense oligonucleotides (AONs), it is possible to modulate pre-mRNA splicing eliminating mutated exons and restoring dystrophin open reading frame. To overcome the hurdles in using AONs for therapeutic interventions, we exerted engineered human DMD stem cells with a lentivirus, which permanently and efficiently delivered the cloned AONs. Here we describe for the first time the exosome-mediated release of AONs from engineered human DMD CD133+ stem cells allowing the rescue of murine dystrophin expression. Finally, upon release, AONs could be internalized by host cells suggesting a potential role of exosomes acting as vesicular carriers for DMD gene therapy.
Export Options
About this article
Cite this article as:
Meregalli Mirella, Farini Andrea, Sitzia Clementina, Beley Cyriaque, Razini Paola, Cassinelli Letizia, Colleoni Federica, Frattini Paola, Santo Nadia, Galbiati Elisabetta, Prosperi Davide, Tavelli Alessandro, Belicchi Marzia, Garcia Luis and Torrente Yvan, Stem Cell-Mediated Exon Skipping of the Dystrophin Gene by the Bystander Effect, Current Gene Therapy 2015; 15 (6) . https://dx.doi.org/10.2174/1566523215666150929111400
DOI https://dx.doi.org/10.2174/1566523215666150929111400 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets Mesoporous Materials Used in Medicine and Environmental Applications
Current Topics in Medicinal Chemistry Immunity to Tuberculosis and Novel Therapeutic Strategies
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Potential of Alphavirus Vectors in the Treatment of Advanced Solid Tumors
Recent Patents on Anti-Cancer Drug Discovery The Role of Stress Proteins in Prostate Cancer
Current Genomics Application of Proteome Analysis to the Assessment of Prognosis and Response Prediction in Clinical Oncology
Current Cancer Drug Targets P-Selectin Glycoprotein Ligand-1 as a Potential Target for Humoral Immunotherapy of Multiple Myeloma (Supplementry Material)
Current Cancer Drug Targets Spinal Cord Injury Changes Cytokine Transport
CNS & Neurological Disorders - Drug Targets The Immunological Side-Effects of Sedative Agents in the Intensive Care Unit
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Signal Transduction Pathways of Inflammatory Gene Expressions and Therapeutic Implications
Current Pharmaceutical Design Chemistry of Bis-Spiroacetal Systems: Natural Products, Synthesis and Stereochemistry
Current Organic Chemistry Recent Patents on Nucleic Acid-Based Antiviral Therapeutics
Recent Patents on Anti-Infective Drug Discovery Colloidal Nanocarriers as Versatile Targeted Delivery Systems for Cervical Cancer
Current Pharmaceutical Design Three-Dimensional Intravenous Digital Subtraction Angiography Using Flat Panel Detector System in Vascular Mapping of the External Carotid Artery: A Comparison with 3-Dimensional Computed Tomography Angiography
Current Medical Imaging Cell Metabolism Under Microenvironmental Low Oxygen Tension Levels in Stemness, Proliferation and Pluripotency
Current Molecular Medicine Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Dual Topoisomerase I / II Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Implications of Nanoscale Based Drug Delivery Systems in Delivery and Targeting Tubulin Binding Agent, Noscapine in Cancer Cells
Current Drug Metabolism Application of Molecular Diagnostics to the Evaluation of the Surgical Approach to Thyroid Cancer
Current Genomics Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology